|
시장보고서
상품코드
2067727
미국의 비침습적 암 진단 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 적응증별, 최종사용자별 및 부문별 예측(2026-2033년)U.S. Non-Invasive Cancer Diagnostics Market Size, Share, & Trends Analysis Report By Product (Pathology-based Instruments, Imaging Instruments), By Technology, By Indication, By End User, And Segment Forecasts, 2026 - 2033 |
||||||
미국 비침습적 암 진단 시장 개요
미국의 비침습적 암 진단 시장 규모는 2025년에 270억 8,000만 달러로 추정되며, 2033년에는 475억 2,000만 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 7.4%로 성장할 것으로 전망되고 있습니다.
이러한 성장은 진단 기술의 지속적인 발전, 암 유병률의 증가, 조기 발견 및 치료 개선을 목표로 한 민간 및 공공 기관 양측의 노력 증가에 힘입어 이루어지고 있습니다.
미국의 비침습적 암 진단 산업의 성장은 상용화 및 혁신 역량을 강화하기 위한 기업의 전략적 확장 노력에 힘입어 더욱 가속화되고 있습니다. 예를 들어 2025년 6월, Dxcover는 세계 최대 생명과학 시장인 미국에서 AI를 활용한 암 검사 ‘PANAROMIC’의 상용화를 가속화하기 위해 내슈빌에 미국 본사를 설립했습니다. 이 새로운 시설은 파트너십, 현지 생산, 연구개발(R&D)을 지원함으로써, 해당 기업의 비침습적이고 비용 대비 효과가 높은 암 선별 검사 플랫폼을 강화하는 동시에 조기 발견 능력을 확대하게 될 것입니다.
또한 환자의 예후를 개선할 수 있는 조기적이고 정확하며 비침습적인 검출법에 대한 수요가 높아지고 있습니다. 혈액 검사 및 다중 암 선별 기술의 발전은 적시 진단과 임상 현장에서의 보다 광범위한 도입을 더욱 촉진하고 있습니다. 예를 들어 2025년 9월, 엑사크트 사이언시스(Exact Sciences)는 미국 최초로 다중 암 조기 검출 혈액 검사인 ‘캔서가드(Cancerguard)’를 출시했습니다. 이 검사는 여러 바이오마커를 통해 50종 이상의 암을 식별할 수 있습니다. 이 검사는 조기 진단에 있으며, 과제를 해결하는 것을 목표로 하며, 높은 민감도와 특이도를 보이고 있습니다. 또한 기존의 선별 검사 방법과 병행함으로써 더 조기 발견이 가능해지며, 치료 성과 향상에 기여할 것으로 기대됩니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 미국의 비침습적 암 진단 시장 : 요인, 동향, 시장 규모
제4장 미국의 비침습적 암 진단 시장 : 제품별, 추정·동향 분석
제5장 미국의 비침습적 암 진단 시장 : 기술별, 추정·동향 분석
제6장 비침습적 암 진단 시장 : 적응증별 비즈니스 분석
제7장 비침습적 암 진단 시장 : 최종사용자별 비즈니스 분석
제8장 경쟁 구도
KSA 26.07.01U.S. Non-Invasive Cancer Diagnostics Market Summary
The U.S. non-invasive cancer diagnostics market size was estimated at USD 27.08 billion in 2025 and is projected to reach USD 47.52 billion in 2033, growing at a CAGR of 7.4% from 2026 to 2033. The growth is driven by the continuous advancements in diagnostic technologies, the rising prevalence of cancer, and increasing initiatives by both private and public organizations aimed at enhancing early detection and treatment.
The U.S. non-invasive cancer diagnostics industry's growth is further driven by strategic expansion initiatives by companies to strengthen commercialization and innovation capabilities. For instance, in June 2025, Dxcover launched its U.S. headquarters in Nashville to accelerate the commercialization of its AI-powered PANAROMIC cancer test in the world's largest life sciences market. The new facility will support partnerships, local manufacturing, and R&D, strengthening its non-invasive, cost-effective cancer screening platform and expanding early detection capabilities.
In addition, increasing demand for early, accurate, and minimally invasive detection methods that improve patient outcomes. Advancements in blood-based and multi-cancer screening technologies are further supporting timely diagnosis and wider clinical adoption. For instance, in September 2025, Exact Sciences launched Cancerguard, a first-of-its-kind multi-cancer early detection blood test in the U.S., capable of identifying over 50 cancer types through multiple biomarkers. The test aims to address gaps in early diagnosis, demonstrating strong sensitivity and high specificity, and is expected to improve outcomes by enabling earlier detection alongside existing screening methods.
U.S. Non-invasive Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. non-invasive cancer diagnostics market report based on product, technology, indication, and end user:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Pathology-based Instruments
- Polymerase Chain Reaction (PCR) Instruments
- Next-generation Sequencing (NGS) Instruments
- Microarrays
- Imaging Instruments
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Positron Emission Tomography (PET)
- Mammography
- Others (Ultrasound, etc.)
- Consumables
- Kits & Reagents
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Imaging
- Liquid Biopsy
- Immunoassay
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Liver Cancer
- Cervical Cancer
- Skin Cancer
- Others (Thyroid Cancer, etc.)
- End User Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Others (Academic & Research Institutes, etc.)
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Technology
- 1.2.3. Indication
- 1.2.4. End User
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Non-Invasive Cancer Diagnostic Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. U.S. Non-Invasive Cancer Diagnostic Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.1. Industry Analysis - Porter's
- 3.4. U.S. Non-Invasive Cancer Diagnostic Market: Pipeline Analysis
Chapter 4. U.S. Non-Invasive Cancer Diagnostic Market: Product Estimates & Trend Analysis
- 4.1. Product Segment Dashboard
- 4.2. U.S. Non-Invasive Cancer Diagnostic Market: Product Movement Analysis
- 4.3. U.S. Non-Invasive Cancer Diagnostic Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Instruments
- 4.4.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Pathology-based Instruments
- 4.4.2.1. Pathology-based Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2.2. Polymerase Chain Reaction (PCR) Instruments
- 4.4.2.2.1. Polymerase Chain Reaction (PCR) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2.3. Next-generation Sequencing (NGS) Instruments
- 4.4.2.3.1. Next-generation Sequencing (NGS) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2.4. Microarrays
- 4.4.2.4.1. Microarrays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Imaging Instruments
- 4.4.3.1. Imaging Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.2. Magnetic Resonance Imaging (MRI)
- 4.4.3.2.1. Magnetic Resonance Imaging (MRI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.3. Computed Tomography (CT)
- 4.4.3.3.1. Computed Tomography (CT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.4. Positron Emission Tomography (PET)
- 4.4.3.4.1. Positron Emission Tomography (PET) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.5. Mammography
- 4.4.3.5.1. Mammography Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3.6. Others (Ultrasound, etc.)
- 4.4.3.6.1. Others (Ultrasound, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Consumables
- 4.5.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Kits & Reagents
- 4.6.1. Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Non-Invasive Cancer Diagnostic Market: Technology Estimates & Trend Analysis
- 5.1. Technology Segment Dashboard
- 5.2. U.S. Non-Invasive Cancer Diagnostic Market: Technology Movement Analysis
- 5.3. U.S. Non-Invasive Cancer Diagnostic Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
- 5.4. Imaging
- 5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 5.5. Liquid Biopsy
- 5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 5.6. Immunoassay
- 5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 6. Non-Invasive Cancer Diagnostic Market: Indication Business Analysis
- 6.1. Indication Segment Dashboard
- 6.2. U.S. Non-Invasive Cancer Diagnostic Market: Indication Movement Analysis
- 6.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 6.4. Lung Cancer
- 6.4.1. Lung Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Breast Cancer
- 6.5.1. Breast Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Colorectal Cancer
- 6.6.1. Colorectal Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Prostate Cancer
- 6.7.1. Prostate Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8. Blood Cancer
- 6.8.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.9. Liver Cancer
- 6.9.1. Liver Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.10. Cervical Cancer
- 6.10.1. Cervical Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.11. Skin Cancer
- 6.11.1. Skin Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12. Others (Thyroid Cancer, etc.)
- 6.12.1. Others (Thyroid Cancer, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Non-Invasive Cancer Diagnostic Market: End User Business Analysis
- 7.1. End User Segment Dashboard
- 7.2. U.S. Non-Invasive Cancer Diagnostic Market: End User Movement Analysis
- 7.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
- 7.4. Hospitals
- 7.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Diagnostic Laboratories
- 7.5.1. Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Others (Academic & Research Institutes, etc.)
- 7.6.1. Others (Academic & Research Institutes, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key company heat map analysis, 2025
- 8.4. Company Profiles
- 8.4.1. Abbott Laboratories
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. GE Healthcare
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Service benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Siemens Healthineers AG
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Service benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. Koninklijke Philips N.V.
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Service benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Canon Medical Systems
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Service benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. F. Hoffmann-La Roche Ltd
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Service benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Illumina, Inc.
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Service benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Guardant Health, Inc.
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Service benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Thermo Fisher Scientific Inc.
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Service benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. FONAR Corporation
- 8.4.10.1. Financial performance
- 8.4.10.2. Service benchmarking
- 8.4.10.3. Strategic initiatives
- 8.4.1. Abbott Laboratories
